Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation

Jannik Langtved Pallisgaard; Gunnar Hilmar Gislason; Christian Torp-Pedersen; Christina Ji-Young Lee; Caroline Sindet-Pedersen; Laila Staerk; Jonas Bjerring Olesen; Tommi Bo Lindhardt

doi:10.1371/journal.pone.0161768

Loading metrics

Open Access

Peer-reviewed

Research Article

Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation

Jannik Langtved Pallisgaard ,

* E-mail: jannikjannik@gmail.com

Affiliations Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
⨯
Gunnar Hilmar Gislason,

Affiliations Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, The Danish Heart Foundation, Copenhagen, Denmark, The National Institute of Public Health, University of Southern Denmark, Odense, Denmark
⨯
Christian Torp-Pedersen,

Affiliation Institute of Health, Science and Technology, Aalborg University, Aalborg, Denmark
⨯
Christina Ji-Young Lee,

Affiliation Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark
⨯
Caroline Sindet-Pedersen,

Affiliations Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
⨯
Laila Staerk,

Affiliations Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
⨯
Jonas Bjerring Olesen,

Affiliation Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark
⨯
Tommi Bo Lindhardt

Affiliation Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark
⨯

Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation

Jannik Langtved Pallisgaard,
Gunnar Hilmar Gislason,
Christian Torp-Pedersen,
Christina Ji-Young Lee,
Caroline Sindet-Pedersen,
Laila Staerk,
Jonas Bjerring Olesen,
Tommi Bo Lindhardt

Published: August 25, 2016
https://doi.org/10.1371/journal.pone.0161768

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Hemorrhage
Is the Subject Area "Hemorrhage" applicable to this article?

Thanks for your feedback.
Cardiovascular disease risk
Is the Subject Area "Cardiovascular disease risk" applicable to this article?

Thanks for your feedback.
Atrial fibrillation
Is the Subject Area "Atrial fibrillation" applicable to this article?

Thanks for your feedback.
Ischemic stroke
Is the Subject Area "Ischemic stroke" applicable to this article?

Thanks for your feedback.
Hemorrhagic stroke
Is the Subject Area "Hemorrhagic stroke" applicable to this article?

Thanks for your feedback.
Anticoagulant therapy
Is the Subject Area "Anticoagulant therapy" applicable to this article?

Thanks for your feedback.
Medical risk factors
Is the Subject Area "Medical risk factors" applicable to this article?

Thanks for your feedback.
Epidemiology
Is the Subject Area "Epidemiology" applicable to this article?

Thanks for your feedback.